SELEPEN INJ 40MCG/ML USP DIN 01945335
Status: Cancelled Post Market
Holder: LYPHOMED, DIVISION OF FUJISAWA CANADA INC.
Molecule: SELENIUM (SELENIOUS ACID)
Health Canada record
| Active ingredient(s) | SELENIUM (SELENIOUS ACID) 40 MCG |
|---|---|
| Dosage form | Liquid |
| Route | Intravenous |
| Schedule | ETHICAL |
| Class | Human |
| ATC | B05XA31 ELECTROLYTES IN COMB WITH OTHER DRUGS |
| Original market date | 31-Dec-1984 |
| Current status date | 30-Jan-1997 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SELENIUM (SELENIOUS ACID)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 01986007 | MICRO SE | SANDOZ CANADA INCORPORATED | Solution | SELENIUM (SELENIOUS ACID) 40 MCG | Marketed |
| 02558254 | SELENIOUS ACID INJECTION, USP | FRESENIUS KABI CANADA LTD | Solution | SELENIUM (SELENIOUS ACID) 60 MCG | Approved |
| 02139316 | SELEPEN | PHARMACEUTICAL PARTNERS OF CANADA INC | Solution | SELENIUM (SELENIOUS ACID) 40 MCG | Cancelled Post Market |